About us

OVERVIEW

A Global Leader in
RNA Therapeutics for Intractable
Genetic Brain Diseases

Global Top-Tier
R&D Capabilities
  • Global Leader in Brain Somatic Mutation Research
  • World-Class Expertise in Drug Development and Business Development
Unique Platform Edge
  • Low-frequency Mutation Detection Technology
  • Brain Disease—Specific Translational Research Models
  • ASO Drug Discovery Platform Optimized for Neurological Disorders
Innovative R&D Pipeline
  • First-in-Class Drugs Based on Novel Targets
  • In-house ASO Pipeline & Platform Based Collaboration Pipeline
  • Expansion into Neurodegenerative Diseases
Efficient R&D through
Partnership
  • Early Stage L/O Based on Proof-of-Mechanism for Novel Targets
  • L/O based on clinical PoC
  • Platform-Based Research Collaboration

Leadership

  • Cheolwon Park President & CEO
    • Former CEO, KoBioLabs Inc.
    • Former Head of BD and R&D Division, Alvogen Korea Ltd.
    • Former BD Team Leader, Pharmaceutical Business Unit, CJ CheilJedang Corporation
    • Former R&D and Business Development, LG Life Sciences (or LG Chem Life Sciences Division)
    • B.S. and M.S. in Pharmacy, Seoul National University
  • Jeong Ho Lee Vice President & CSO
    • Endowed Chair Professor, KAIST
    • Director, Research Center for Somatic Mutation in the Brain
    • Former Postdoctoral Researcher, UC San Diego / HHMI Neurogenetics Lab
    • Ph.D. in Neuropharmacology, Yonsei University College of Medicine
    • M.D., Yonsei University College of Medicine
  • SungJi Kim Managing Director / CTO
    • Former Head of Development Division, KoBioLabs Inc.
    • Former Head of Business Strategy and Development, Alvogen-Dreampharma
    • Former Business Strategy and Development, CJ CheilJedang Corporation
    • Former Strategic Alliances, LG Life Sciences
    • M.S. in Medicinal Chemistry, Department of Pharmacy, Seoul National University
    • B.S. in Pharmaceutical Sciences, College of Pharmacy, Seoul National University
  • Sang Kweon Jeon Managing Director/Strategic planning
    • Former Executive, CJ Corporation & CJ CheilJedang Corporation
    • Former Head of Pharmaceutical Business Division & Corporate Strategy, CG Invites
    • Former Head of Strategic Planning, MitoImmune Therapeutics Co., Ltd.
    • Former Corporate Strategy, LG Chem
    • Former R&D Strategic planning & Corporate Strategy, LG Life Sciences
    • M.S. in Biology, Yonsei University
    • B.S. in Biological Sciences, Yonsei University
  • Junghyun Lee Managing Director/ Management planning
    • Korea Certified Valuation Analyst
    • Former Overseas Sales, KOS Group
    • Former Samsung Electronics BTL Marketing Program Operations
    • Former Executive Planning dept., Carlson Wagonlit Travel Korea
    • B.A. in International Management and English, Dongduk Women's University
  • Hyung Ki KimSenior Managing Director/ Management support
    • Former CEO, PLENUS Investment Former Legal Team
    • Former Legal Team, SK Broadband
    • Former Portfolio Management Team at HI Investment & Securities (Current, IM Securities) and Kyobo Securities
    • M.A. in Business Strategy, Yonsei University
    • B.A. in Business Administration, Yonsei University
  • Jeong-Wook GhimManaging Director/ Evaluation Center
    • Former Research Fellow, Center for Synaptic Brain Disorders, IBS
    • Postdoctoral Researcher, Ajou University College of Medicine
    • Ph.D., Computational and Statisticis Physics, POSTECH
    • M.A. Computational and Statistics Physics, POSTECH
    • B.S. Physics, Chungang University
  • Sang Min ParkDirector/ Discovery Center
    • Former Team Leader, Neuro D. Team, Sovargen
    • Ph.D., Graduate School of Medical Science and Engineering, KAIST
    • B.S. Department of Biological Science, Sungkyunkwan University